Fibromyalgia future or investigational therapies: Difference between revisions
Created page with "__NOTOC__ {{Fibromyalgia}} {{CMG}} ==Overview== ==Future or Investigational Therapies== Milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), is availab..." |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
[[Milnacipran]], a [[serotonin-norepinephrine reuptake inhibitor]] (SNRI), is available in parts of Europe where it has been safely prescribed for other disorders. On May 22nd, 2007, a Phase III study demonstrated statistically significant therapeutic effects of [[Milnacipran]] as a treatment of fibromyalgia syndrome. | [[Milnacipran]], a [[serotonin-norepinephrine reuptake inhibitor]] (SNRI), is available in parts of Europe where it has been safely prescribed for other disorders. On May 22nd, 2007, a Phase III study demonstrated statistically significant therapeutic effects of [[Milnacipran]] as a treatment of fibromyalgia syndrome. Currently, only initial top-line results are available, but further analyses will be completed in the coming weeks. If approved by the [[FDA]], [[Milnacipran]] could be distributed in the United States as early as summer, 2008. | ||
Among the more controversial therapies involves the use of [[guaifenesin]] | Among the more controversial therapies involves the use of [[guaifenesin]]. Called St. Amand's protocol or the [[guaifenesin protocol]], the efficacy of [[guaifenesin]] in treating fibromyalgia has not been proven in properly designed research studies. Indeed, a controlled study conducted by researchers at Oregon Health Science University in Portland failed to demonstrate any benefits from this treatment, and the lead researcher has suggested that the anecdotally reported benefits were due to placebo suggestion. The results of the study have since been contested by Dr. St. Amand, who was a co-author of the original research report.<ref>{{cite journal | url = http://www.fibromyalgiatreatment.com/Research_Oregon.htm | title = A Response To The Oregon Study's Implication | accessdate = 2007-06-23 | first = R. Paul | last = St. Amand | journal = Clinical Bulletin of Myofascial Therapy | volume = 2 | issue = 4 | year = 1997 }}</ref> | ||
[[Dextromethorphan]] is an over-the-counter cough medicine with activity as an [[NMDA receptor antagonist]]. | [[Dextromethorphan]] is an over-the-counter cough medicine with activity as an [[NMDA receptor antagonist]]. It has been used in research settings to investigate the nature of fibromyalgia pain<ref name="pmid15890634">{{cite journal |author=Staud R, Vierck CJ, Robinson ME, Price DD |title=Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects |journal=The journal of pain : official journal of the American Pain Society |volume=6 |issue=5 |pages=323-32 |year=2005 |pmid=15890634 |doi=10.1016/j.jpain.2005.01.357}}</ref>; however, there are no controlled trials of safety or efficacy in clinical use. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 20:31, 28 July 2017
|
Fibromyalgia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fibromyalgia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Fibromyalgia future or investigational therapies |
|
Fibromyalgia future or investigational therapies in the news |
|
Risk calculators and risk factors for Fibromyalgia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), is available in parts of Europe where it has been safely prescribed for other disorders. On May 22nd, 2007, a Phase III study demonstrated statistically significant therapeutic effects of Milnacipran as a treatment of fibromyalgia syndrome. Currently, only initial top-line results are available, but further analyses will be completed in the coming weeks. If approved by the FDA, Milnacipran could be distributed in the United States as early as summer, 2008.
Among the more controversial therapies involves the use of guaifenesin. Called St. Amand's protocol or the guaifenesin protocol, the efficacy of guaifenesin in treating fibromyalgia has not been proven in properly designed research studies. Indeed, a controlled study conducted by researchers at Oregon Health Science University in Portland failed to demonstrate any benefits from this treatment, and the lead researcher has suggested that the anecdotally reported benefits were due to placebo suggestion. The results of the study have since been contested by Dr. St. Amand, who was a co-author of the original research report.[1]
Dextromethorphan is an over-the-counter cough medicine with activity as an NMDA receptor antagonist. It has been used in research settings to investigate the nature of fibromyalgia pain[2]; however, there are no controlled trials of safety or efficacy in clinical use.
References
- ↑ St. Amand, R. Paul (1997). "A Response To The Oregon Study's Implication". Clinical Bulletin of Myofascial Therapy. 2 (4). Retrieved 2007-06-23.
- ↑ Staud R, Vierck CJ, Robinson ME, Price DD (2005). "Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects". The journal of pain : official journal of the American Pain Society. 6 (5): 323–32. doi:10.1016/j.jpain.2005.01.357. PMID 15890634.